other material
confidence high
sentiment neutral
materiality 0.55
ArriVent BioPharma expands at-the-market equity program by up to $250M
ArriVent BioPharma, Inc.
- Filed prospectus supplement on May 11, 2026 to sell up to $250,000,000 of common stock via ATM.
- Jefferies LLC named as sales agent under existing Open Market Sale Agreement dated Feb 3, 2025.
- Proceeds will be used for general corporate purposes; no specific use disclosed.
- Offering is made under automatic shelf registration statement (Form S-3ASR, File 333-284661).